Cash, cash equivalents and marketable securities as of December 31, 2023 were $753M compared to $876M at September 30, 2023. Based upon the Company’s current operating plan, Sage anticipates that its existing cash, cash equivalents and marketable securities, along with the milestone payment received in January 2024, anticipated funding from ongoing collaborations, and estimated revenues, will support its operations into 2026. The Company does not anticipate receipt of any milestone payments from collaborations in the remainder of 2024. The Company anticipates operating expenses will decrease in 2024 relative to 2023. With the availability of ZURZUVAE as an additional treatment for women with PPD, the Company anticipates ZULRESSO revenues will decrease over time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- SAGE Earnings this Week: How Will it Perform?
- Sage Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
- SAGE Therapeutics Stockholders Approve Employee Stock Plan
- SAGE Therapeutics Secures New Cambridge Headquarters Lease
- Sage Therapeutics price target raised to $22 from $20 at Truist